Streetbeat News

Earnings

OM

Outset Medical has reiterated its 2023 revenue guidance of approximately $130 million, which is slightly lower than the estimated $132 million. The company also maintains its gross margin guidance for the year to be in the low-20% range, exiting the fourth quarter in the mid-20% range.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:41 am

EOLS

Evolus has updated its FY23 revenue forecast to $194M-$198M, exceeding the previous estimate of $190.81M. This represents a YoY growth of over 30%. The company also expects its adjusted gross profit margin for FY23 to be between 68% and 71%, and its full-year non-GAAP operating expenses to be between $153M and $158M. Evolus projects its total net revenue can reach $700 million by 2028, a CAGR of 29%, driven by its existing aesthetic neurotoxin business and the anticipated launch of the Evolysse™ HA dermal filler product line in 2025.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:40 am

ENVX

Enovix Corporation (ENVX) expects Q4 2023 revenue to increase to between $3 million and $4 million, up from an estimated $530K, due to partial quarter from Routejade and continued shipments of silicon batteries for the U.S. Army program. The company also revised its operational cash use forecast for 2023 from $120 million to $110 million and CapEx forecast from $70 million to $65 million due to strategic realignment of Fab1 and timing of Gen2 equipment installation in Malaysia.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:39 am

ODD

Oddity Tech has raised its FY23 EPS from $1.11-$1.17 to $1.21-$1.23, and revenue from $475M-$480M to $493M-$497M. This is due to strong Q3 results, leading to higher revenue, profit margins, and earnings than previously expected. The company now expects year-over-year growth between 52% and 53%, gross margins of approximately 70.0%, and adjusted EBITDA between $104 million and $105 million.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:37 am

ODD

Oddity Tech has provided its Q4 2023 guidance, expecting net revenue between $82M-$85M, representing YoY growth of 22-26%, and adjusted EBITDA between $13M-$14M. The company also anticipates an adjusted diluted EPS of $0.10-$0.12, with a stock-based compensation expense of approximately $8M.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:36 am

CTKB

Cytek Biosciences has projected its FY23 total revenue to be between $188 million and $192 million, indicating a growth of 15% to 17% over FY22. The forecast includes flat organic business revenue compared to 2022 and inorganic revenue of $25 million to $30 million from the recently acquired Luminex flow cytometry and imaging business.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:33 am

VCYT

Veracyte has increased its full-year 2023 total revenue guidance from $342M-$350M to $352M-$354M, representing a year-over-year growth of approximately 19%. This is an improvement compared to the prior guidance of $342M-$350M.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:31 am

BMBL

Bumble has revised its Q4 2023 revenue forecast to $272M-$278M, lower than the estimated $286.56M. This includes a $6M lower foreign currency benefit and a $1M unfavorable impact from the Middle East crisis, primarily affecting Bumble App Revenue. Adjusted EBITDA is expected to be between $72M-$75M. The actual results may differ significantly due to various factors.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:30 am

BLND

Blend Labs has provided its Q4 2023 guidance, expecting Blend Platform Revenue to be between $25M-$30M, Title Revenue between $9.5M-$10.5M, and Consolidated Revenue between $34.5M-$40.5M. This is lower than the estimated $40.19M. The company anticipates a 5% YoY decline in mortgage volumes from 4Q22 to 4Q23. Economic conditions and levels of real estate and mortgage activity remain uncertain.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:28 am

AMPL

Amplitude has provided its Q4 and FY23 financial outlook, expecting Q4 EPS of $0.02-$0.03 and revenue of $71.3M-$71.9M, and FY23 EPS of $0.05-$0.06 and revenue of $276.2M-$276.8M. These estimates exceed the current market expectations. However, the company warns that these are forward-looking statements and actual results may differ materially.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:26 am